Tolerability of trichostatin A for people with relapsed or refractory blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, open-label, single-agent trial giving trichostatin A to adults with relapsed or refractory hematologic malignancies to characterize safety and tolerability. Participants must have measurable or evaluable disease, an ECOG performance status of 0–2, and have exhausted available standard therapies. Study procedures include regular clinical exams, laboratory monitoring, cardiac monitoring, and disease assessments to track adverse events and any signs of response. The trial is conducted at Vanda investigational sites and will follow participants through dosing and predefined safety follow-up periods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject is ≥ 18 years at the time of signing informed consent;
* Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
* Presence of measurable or evaluable disease;
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
* Contraceptives or other approved avoidance of pregnancy measures

Exclusion Criteria:

* Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
* Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
* Undergone major surgery ≤ 2 weeks prior to starting study drug;
* Evidence of mucosal or internal bleeding;
* Impaired cardiac function or conduction defect;
* Concurrent severe and/or uncontrolled medical conditions

Where it's running

• Vanda Investigational Site
  Biała Podlaska, Poland Recruiting
• Vanda Investigational Site
  Katowice, Poland Recruiting
• Vanda Investigational Site
  Opole, Poland Recruiting
• Vanda Investigational Site
  Warsaw, Poland Recruiting
• Vanda Investigational Site
  Washington D.C., District of Columbia, United States Withdrawn
• Vanda Investigational Site
  Lafayette, Indiana, United States Completed

Study contacts

• Study coordinator: Vanda Pharmaceuticals
• Email: clinicaltrials@vandapharma.com
• Phone: 202-734-3400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QLS2309 injections for adults with CD70-positive relapsed or refractory blood cancers.

  This trial will try QLS2309 injections to see if they are safe, tolerated, and show early anti-cancer effects in adults with CD70-positive relapsed or refractory blood cancers.

  Recruiting Phase 1 Qilu Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07173595

• Evaluating SCTC21C for patients with CD38+ blood cancers

  This study is testing a new treatment called SCTC21C to see if it can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting Phase 1 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT06252298

• Cell injection for patients with relapsed or refractory CD7-positive NK/T cell malignancies

  This study is testing a new cell therapy for people with hard-to-treat CD7-positive NK/T cell lymphoma to see if it is safe and helps improve their condition.

  Recruiting Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06732492

• Testing KK2845 for patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new drug called KK2845 to see if it can help people with relapsed or refractory acute myeloid leukemia feel better and improve their treatment options.

  Recruiting at 17 sites Phase 1 Kyowa Kirin Co., Ltd. · Kamogawa, Chiba and 16 other locations · NCT06812104

• BAFFR CAR-T therapy for relapsed or treatment-resistant B‑cell cancers

  This study will try BAFFR-directed CAR-T cell therapy in adults whose B‑cell cancers have come back or not responded to prior treatments to see if it is safe and works.

  Recruiting Tongji Hospital · Wuhan · NCT07345728

• IASO208 injection for relapsed or refractory B‑cell lymphomas

  This trial will test IASO208 injections in adults (18–75) whose B‑cell lymphoma has relapsed or not responded to prior standard treatment to see if it is safe and helps control the disease.

  Recruiting Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07309900

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.